{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/rheumatoid-arthritis/goals-outcome-measures/nice-quality-standards/","result":{"pageContext":{"chapter":{"id":"3181265d-dee9-5587-974d-b4bae95c10ee","slug":"nice-quality-standards","fullItemName":"NICE quality standards","depth":2,"htmlHeader":"<!-- begin field 35d0f2c6-70ed-4894-a1ee-a508d4aa4b97 --><h2>NICE quality standards</h2><!-- end field 35d0f2c6-70ed-4894-a1ee-a508d4aa4b97 -->","summary":null,"htmlStringContent":"<!-- begin item e409e14f-a8ce-4e44-b7aa-202fba5c0b55 --><!-- begin field c2a67e0f-34a8-4e3a-ae5e-28dfcc7b9789 --><p><a data-hyperlink-id=\"7bc2c9f0-8131-4bad-87bc-a920009814e0\" href=\"https://www.nice.org.uk/guidance/qs33/chapter/quality-statement-1-referral#quality-statement-1-referral\" target=\"_top\">Statement 1</a> Adults with suspected persistent synovitis affecting more than 1 joint, or the small joints of the hands and feet, are referred to rheumatology services within 3 working days of presenting in primary care. Statement 2 Adults with active rheumatoid arthritis start conventional disease-modifying anti-rheumatic drug (cDMARD) monotherapy within 6 weeks of referral, with monthly monitoring until their treatment target is met.</p><p><a data-hyperlink-id=\"abf371bc-ab90-4a75-9dda-a9200098154b\" href=\"https://www.nice.org.uk/guidance/qs33/chapter/quality-statement-2-assessment#quality-statement-2-assessment\" target=\"_top\">Statement 2</a> People with suspected persistent synovitis are assessed in a rheumatology service within 3 weeks of referral.</p><p><a data-hyperlink-id=\"42df653e-cd9e-487d-a7b7-a92000981559\" href=\"https://www.nice.org.uk/guidance/qs33/chapter/quality-statement-3-starting-treatment#quality-statement-3-starting-treatment\" target=\"_top\">Statement 3</a> Adults with rheumatoid arthritis are given opportunities throughout the course of their disease to take part in educational activities that support self-management.</p><p><a data-hyperlink-id=\"3b0f0913-8e36-44b0-86fa-a92000981576\" href=\"https://www.nice.org.uk/guidance/qs33/chapter/quality-statement-4-education-and-self-management#quality-statement-4-education-and-self-management\" target=\"_top\">Statement 4</a> Adults with rheumatoid arthritis and disease flares or possible treatment-related side effects receive advice within 1 working day of contacting rheumatology services.</p><p><a data-hyperlink-id=\"223646df-cd77-4c93-ab64-a9200098157f\" href=\"https://www.nice.org.uk/guidance/qs33/chapter/quality-statement-5-disease-control#quality-statement-5-disease-control\" target=\"_top\">Statement 5</a> Adults with rheumatoid arthritis have a comprehensive annual review that is coordinated by rheumatology services.</p><p><a data-hyperlink-id=\"6e700f42-c1ee-426b-b0ed-a92000981584\" href=\"https://www.nice.org.uk/guidance/qs33/chapter/quality-statement-6-rapid-access#quality-statement-6-rapid-access\" target=\"_top\">Statement 6</a> People with rheumatoid arthritis and disease flares or possible drug related side effects receive advice within 1 working day of contacting the rheumatology service.</p><p><a data-hyperlink-id=\"9bfd38ec-1277-48f3-847d-a92000981592\" href=\"https://www.nice.org.uk/guidance/qs33/chapter/quality-statement-7-annual-review#quality-statement-7-annual-review\" target=\"_top\">Statement 7</a> People with rheumatoid arthritis have a comprehensive annual review that is coordinated by the rheumatology service.</p><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/rheumatoid-arthritis/references/\">NICE, 2018c</a>]</p><!-- end field c2a67e0f-34a8-4e3a-ae5e-28dfcc7b9789 --><!-- end item e409e14f-a8ce-4e44-b7aa-202fba5c0b55 -->","topic":{"id":"80425c66-11ed-5a54-aecf-455f339cb0cd","topicId":"d9596563-d663-48ca-8d6a-4ddeb263b46e","topicName":"Rheumatoid arthritis","slug":"rheumatoid-arthritis","lastRevised":"Last revised in April 2020","chapters":[{"id":"e5b4cb7c-c830-59e0-a369-a8151bd28e7c","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"28d53d37-f5b2-5ab0-bd6f-6c6858fc63e4","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"8eb76d85-83a8-5bb1-be89-15a9e86def8d","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"7eba8b39-2fb0-52b0-8988-5d108c1720fa","slug":"changes","fullItemName":"Changes"},{"id":"add57644-4b68-5377-b8ce-b0cc395570f0","slug":"update","fullItemName":"Update"}]},{"id":"62d68b4b-4522-5afb-88fe-48b87fc31a2d","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"f9fe7005-bf48-5a4e-bc7c-08550e792a18","slug":"goals","fullItemName":"Goals"},{"id":"cc0b2b43-25e2-5936-ad94-217419fd0126","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"6a0fead6-ca32-5399-9b1b-22b31fc0c765","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"f76001a5-99f4-5086-bc05-c1cd7535aab0","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"fb29501f-d465-5652-b659-ffb4e5c8e928","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"3181265d-dee9-5587-974d-b4bae95c10ee","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"167941e5-411a-5afd-94af-8e7725b24b1a","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"bb48f4e9-23c4-5828-bccb-666f4dbc512d","slug":"definition","fullItemName":"Definition"},{"id":"06cc7595-3f6c-59d6-929b-964159afde4d","slug":"prevalence-incidence","fullItemName":"Prevalence and incidence"},{"id":"8fb1fc93-039a-5d6b-a86d-aeb61578f11d","slug":"complications","fullItemName":"Complications"}]},{"id":"e352008d-7a0c-55ba-b778-c6218ef4ef69","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"b9d257ab-0ebb-52bf-908a-8ebebe6c550c","slug":"when-to-suspect-ra","fullItemName":"When to suspect RA"},{"id":"25d80dc3-ea8a-5560-8a0b-3a64b87c5690","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"},{"id":"5de822df-3081-5ed6-a21b-e3e2925436bd","slug":"investigations-for-suspected-ra","fullItemName":"Investigations for suspected RA"}]},{"id":"6f1e7941-f462-5d64-8822-8328310b81b9","fullItemName":"Management","slug":"management","subChapters":[{"id":"2ed609a5-1052-56f5-b263-63d4e5325949","slug":"suspected-ra","fullItemName":"Scenario: Suspected RA"},{"id":"0ba5ec6e-3f0f-5157-8e24-55ef24b2cfe9","slug":"confirmed-ra","fullItemName":"Scenario: Confirmed RA"},{"id":"c490cb4d-f228-5c81-b9f2-0ac419b6d60a","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"13cb1ed1-b962-5e8a-88c8-8b7185af06df","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"e875cc8d-258b-5535-9d34-40f03cb150c7","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"9b45cf27-1cfb-591d-a936-5e49910f88ac","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"93bd3cb0-31a7-5acf-bc5f-8858b54e466b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"a24a6436-a685-5277-8c22-524ebe895154","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"4258a438-16bd-591d-bd95-5d6a682e1696","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"58298e48-e237-5259-b79b-da11e96f0a4e","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"6c1abdea-39c1-5537-8e4f-6e6ff3a71736","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"62d68b4b-4522-5afb-88fe-48b87fc31a2d","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}